Premium
Plasma levels of von Willebrand factor in type 2 diabetes patients with and without cardiovascular diseases: A meta‐analysis
Author(s) -
Peng Xun,
Wang Xia,
Fan Mengge,
Zhao Junyu,
Lin Liao,
Liu Ju
Publication year - 2020
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/dmrr.3193
Subject(s) - von willebrand factor , medicine , meta analysis , confidence interval , type 2 diabetes mellitus , diabetes mellitus , pathogenesis , subgroup analysis , gastroenterology , platelet , endocrinology
Summary Chronic vascular complications are the major causes of death and disability of type 2 diabetes mellitus (T2DM) patients. von Willebrand factor (vWF) is involved in pathogenesis of cardiovascular diseases (CVD). Previous studies showed elevated plasma levels of vWF in T2DM patients with CVD, but the association has not been validated. The aim of this meta‐analysis was to compare plasma levels of vWF in T2DM patients with and without CVD. We performed a meta‐analysis based on published case‐control studies of vWF in T2DM patients with and without CVD indexed in PubMed and other databases updated to April 2018. After independently assessing methodological quality and extracting data, 9 eligible studies were obtained including 576 cases and 632 controls. The standard mean difference (SMD) and 95% confidence intervals (95% CI) were calculated using random‐effects model. Meta‐analysis showed that plasma level of vWF was significantly higher in T2DM patients with CVD than T2DM patients without CVD (SMD = 0.61; 95% CI, 0.32‐0.90; P < .00001). Subgroup and sensitivity analyses confirmed the robustness of the results. Plasma levels of vWF are significantly elevated in patients with T2DM complicated by CVD. This study helps further characterize the prognostic value of vWF for cardiovascular complications in T2DM patients.